SRSF2 mutations are seen in 11–15% of patients with MDS, frequently co-existing with RUNX1, IDH1, IDH2, and ASXL1 mutations [283], and confer an inferior overall survival [292,293]. This evidence concerns the gene ASXL1 and myelodysplastic syndrome.